Follow
Pardeep S. Jhund
Pardeep S. Jhund
Verified email at glasgow.ac.uk - Homepage
Title
Cited by
Cited by
Year
Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ...
New England Journal of Medicine 381 (21), 1995-2008, 2019
59932019
Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ...
New England Journal of Medicine 381 (17), 1609-1620, 2019
18902019
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ...
New England Journal of Medicine 387 (12), 1089-1098, 2022
14222022
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
SL Kristensen, R Rørth, PS Jhund, KF Docherty, N Sattar, D Preiss, ...
The lancet Diabetes & endocrinology 7 (10), 776-785, 2019
13212019
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people
PS Jhund, K MacIntyre, CR Simpson, JD Lewsey, S Stewart, A Redpath, ...
Circulation 119 (4), 515-523, 2009
7962009
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology
NM Hawkins, MC Petrie, PS Jhund, GW Chalmers, FG Dunn, ...
European journal of heart failure 11 (2), 130-139, 2009
7762009
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis …
M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, JP Ferreira, ...
The Lancet 396 (10244), 121-128, 2020
5522020
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ...
The Lancet 400 (10354), 757-767, 2022
5252022
PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ...
N Engl J Med 381 (17), 1609-1620, 2019
4882019
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
4852020
Declining risk of sudden death in heart failure
L Shen, PS Jhund, MC Petrie, BL Claggett, S Barlera, JGF Cleland, ...
New England Journal of Medicine 377 (1), 41-51, 2017
4842017
Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
LH Lund, B Claggett, J Liu, CS Lam, PS Jhund, GM Rosano, K Swedberg, ...
European journal of heart failure 20 (8), 1230-1239, 2018
4602018
Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure
K Damman, M Gori, B Claggett, PS Jhund, M Senni, MP Lefkowitz, ...
JACC: Heart Failure 6 (6), 489-498, 2018
3872018
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine …
SL Kristensen, D Preiss, PS Jhund, I Squire, JS Cardoso, B Merkely, ...
Circulation: Heart Failure 9 (1), e002560, 2016
3702016
Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial
MN Kosiborod, PS Jhund, KF Docherty, M Diez, MC Petrie, S Verma, ...
Circulation 141 (2), 90-99, 2020
3542020
Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF
JJV McMurray, AM Jackson, CSP Lam, MM Redfield, IS Anand, J Ge, ...
Circulation 141 (5), 338-351, 2020
3432020
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left …
JJV McMurray, DL DeMets, SE Inzucchi, L Køber, MN Kosiborod, ...
European journal of heart failure 21 (5), 665-675, 2019
3372019
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo …
RR Holman, RL Coleman, JCN Chan, JL Chiasson, H Feng, J Ge, ...
The lancet Diabetes & endocrinology 5 (11), 877-886, 2017
3372017
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
MMY Lee, KJM Brooksbank, K Wetherall, K Mangion, G Roditi, ...
Circulation 143 (6), 516-525, 2021
3302021
Heart failure and socioeconomic status: accumulating evidence of inequality
NM Hawkins, PS Jhund, JJV McMurray, S Capewell
European journal of heart failure 14 (2), 138-146, 2012
3032012
The system can't perform the operation now. Try again later.
Articles 1–20